A large-scale study with a 1-year follow-up was performed to compare 10 days of penicillin V with a short-course treatment (5 days) of other oral antibiotics in the treatment of group A b-hemolytic streptococcus (GABHS) tonsillopharyngitis, to evaluate the efficacy and the incidence of poststreptococcal sequelae. The clinical response rates after completion of therapy were 94.5% in the 5-day group and 93.4% in the penicillin group ( , equivalence test). P ! .001 The GABHS eradication rates were 83.3% in the 5-day group and 84.4% in the penicillin group ( , equivalence test). Poststreptococcal sequelae were rare (5 patients) and did P p .022 not occur in the context of this study. The efficacy of 5-day antibiotic regimens was equivalent to 10 days of penicillin V, but resolution of clinical symptoms was faster in the 5-day group ( , Fisher's exact test). Recurrent tonsillopharyngitis occurs more frequently after treat-P ! .001 ment with penicillin ( , Fisher's exact test). P p .03
if patients have been treated with oral penicillin V for !10 days [10, 11] . In recent studies in which a short-course treatment (4-5 days) with a macrolide or an oral cephalosporin was compared to 10 days of treatment with penicillin V, the shorter treatments were equivalent or superior in eradication of GABHS and in clinical response [12] [13] [14] [15] [16] [17] .
The German Society for Pediatric Infectious Diseases (Munich) was aware that there was general concern that shorter treatment courses might lead to an increased incidence of poststreptococcal sequelae such as ARF or glomerulonephritis. No studies had attempted to monitor the incidence of poststreptococcal sequelae following the short-course regimens and the reference treatment of 10 days of oral penicillin V. It is the objective of this large-scale study to evaluate the clinical and bacteriologic response and the incidence of poststreptococcal sequelae in patients receiving a 5-day regimen versus 10 days of oral penicillin V. For the 5-day regimens, 6 antibiotics that have been shown to be effective in randomized clinical studies, when used in shorter courses for treatment of GABHS tonsillopharyngitis, were selected.
Patients and Methods
Patient population and inclusion criteria. In this multicenter, randomized, open-labeled, controlled study a total of 5318 children ages 1-18 years were enrolled from 137 pediatric practices in Germany between December 1995 and May 1998. The study protocol was approved by the local ethics committee and was carried out in accordance with the Declaration of Helsinki and with national guidelines. Children with a clinical diagnosis of tonsillopharyngitis (fever у38ЊC and у1 of the following: exudate of pharynx or tonsils, erythema of pharynx or tonsils, or cervical lymphadenopathy) and a tonsillopharyngeal swab specimen with a positive reaction by a commercially available rapid antigen test for GABHS were enrolled in the study after written informed consent had been obtained from parents or guardians.
Exclusion criteria.
Patients with a positive rapid test for GABHS that could not be confirmed by culture, a known hypersensitivity to one of the study antibiotics, antimicrobial therapy within 48 h prior to study entry (long-acting antibacterials 2 weeks), intercurrent infections, or additional disorders likely to interfere with the course of the disease under investigation; a medical history of rheumatic fever or glomerulonephritis of the patient or a person living in the same household; malabsorption disorders or other gastrointestinal conditions that prohibit oral administration of antibiotics; or pregnancy, lactation, or serious underlying conditions were excluded from the study.
Antimicrobial treatment. At the initial visit, the patients were randomly assigned, in a 1:2 ratio, to receive either penicillin V oral suspension at 50,000 IU/kg/day (32.7 mg/kg/day), maximum daily dose 2,250,000 IU (1471.5 mg/kg/day), divided into 3 equal doses daily for 10 days or 1 of 6 antimicrobials for 5 days: amoxicillin/ clavulanate 3 times/day at 37.5 mg/kg/day (maximum, 1875 mg/ day), ceftibuten once daily at 9 mg/kg/day (maximum, 400 mg/ day), cefuroxime axetil 2 times/day at 20 mg/kg/day (maximum, 500 mg/day), loracarbef 2 times/day at 15 mg/kg/day (maximum, 400 mg/day), clarithromycin 2 times/day at 15 mg/kg/day (maximum, 500 mg/day), or erythromycin estolate 2 times/day at 40 mg/ kg/day (maximum 1600 mg/day). The study was open labeled: each randomization block for 9 patients contained 3 containers of penicillin V and 1 container of each of the 6 antimicrobials for the 5-day therapy. Dose administration began on the day of randomization (the baseline visit), and patients kept a diary to record medication intake and were requested to return medicine bottles.
Study visits and examination. At baseline, a medical history-including history of tonsillopharyngitis and positive GABHS cultures-was taken, a physical examination was performed, and epidemiological risk factors were recorded. On the basis of the investigator's overall clinical evaluation, an assessment of the disease as mild, moderate, or severe was given. Follow-up visits were scheduled 2-4 days after the end of treatment for assessment of clinical and bacteriological response, 7-9 days after the end of treatment to evaluate the clinical response (final assessment of acute tonsillopharyngitis), and 7-8 weeks after the initiation of therapy to identify asymptomatic carriers. In the 10-day group, an additional visit during treatment, coinciding with the first posttreatment visit in the 5-day group, was scheduled 7-9 days after enrollment. Signs and symptoms of GABHS infection-as well as concomitant diseases and medication-were recorded at baseline, at the first 2 posttreatment visits, and, for the 10-day group, during treatment. Signs and symptoms of rheumatic fever and glomerulonephritis were recorded at all of these visits and at 2 late follow-up visits 6 and 12 months after enrollment into the study. Pediatricians were required to document all recurrences of tonsillopharyngitis during the 1-year follow-up period for every patient included in the study.
Microbiology. Throat swabs were obtained at study entry, at the 2-4-day posttreatment visit and at the follow-up visit 7-8 weeks after initiation of therapy. Swabs were sent by mail in an agar storage-and-transport medium (Venturi Transystem; Copan Italia, Brescia, Italy) to 1 of 2 central laboratories, where they were streaked on a 5% blood agar plate and incubated with 5% CO 2 for 48 h at 37ЊC and then examined for the presence of b-hemolytic streptococci. Susceptibility testing (agar disk diffusion) was performed according to National Committee for Clinical Laboratory Standards guidelines [18] . For patients with positive follow-up cultures, all positive isolates where serotyped by T agglutination patterns, opacity factor typing, and/or M typing, as appropriate [19] , at the Institute for Medical Microbiology, Friedrich-Schiller-University Hospital, Jena, Germany.
Patient evaluation. Children were considered evaluable for efficacy analysis if the throat culture at enrollment was GABHSpositive and if the patient received the full course of study medication and returned for the posttreatment evaluation 2-4 days after the end of treatment.
Clinical assessment. On the basis of the investigators' overall judgment, clinical response was defined as (1) cure (complete resolution of acute symptoms), (2) improvement (partial resolution of acute symptoms), or (3) failure (marginal resolution, persistence or worsening of symptoms, and/or administration of other antimicrobials before or on the day of evaluation).
Bacteriological assessment. Bacteriologic response was graded either (1) eradication (absence of GABHS at the first posttreatment visit) or (2) failure (presence of GABHS at the first posttreatment visit or modification of treatment before culture was taken).
Poststreptococcal sequelae. Signs and symptoms of rheumatic fever were assessed by recording the updated Jones criteria [20] . Diagnosis of glomerulonephritis was based on the pediatrician's assessment with additional recording of signs and symptoms (pain in the kidney region, edema, hypertension, central nervous symptoms in all cases, hematuria, and proteinuria if suspected).
Safety analysis. All patients who received у1 dose of the study medication were included in the safety analysis. Any adverse event during the study was recorded, and the relationship and severity were assessed by the investigator. All events different from "not related" were counted as adverse drug reactions.
Sample size and data analysis. Sample size was calculated to test for a difference in the incidence of poststreptococcal sequelae and to establish equivalence of bacteriological and clinical response in the 2 treatment groups. Calculations to test the proportions based on 1-sided x 2 tests with normal approximation, using N software (idv-Datenanalyse und Versuchsplanung, Gauting, Germany), resulted in 3180 (6 patients/group) patients groups ϫ 530 in the 5-day and 1530 patients in the 10-day treatment group based on the following assumptions and parameters: (1) incidence of poststreptococcal sequelae: on the assumption of an incidence of 3 in 1000 in the 10-day treatment group, an incidence of 18 cases in the 5-day treatment group would show a significant difference ( , 1-sided; ); (2) bacteriological efficacy: compara p 5% b p 20% ing 10 days of penicillin V with the 5-day treatment group, an b p 20% paring 10 days of penicillin V with the 5-day treatment group, cure/ improvement at the 2-4-day posttreatment visit of у94.0%-2.3% would show significant equivalence ( , 1-sided; ). a p 2.5% b p 20% On the assumption of a dropout rate of 13%, 3600 (6 patients/group) patients were randomized into the 5-groups ϫ 600 day treatment group, and 1800 patients were enrolled in 10-day treatment group.
Statistical analysis was carried out using SAS software (SAS Institute, Cary, NC). Equivalence of bacteriological and clinical efficacy was assessed using an exact 1-sided test for proportions [21] . All other variables under investigation were tested with Fisher's exact test (1-sided with the 10-day treatment group as control in the case of poststreptococcal sequelae and 2-sided in all other instances, ). a p 5%
Results

Patient characteristics.
A total of 4782 patients, ages 1-18 years, with acute tonsillopharyngitis and a positive throat culture for GABHS, were enrolled in the study to receive a 5-day oral treatment with cephalosporins (cefuroxime axetil, ceftibuten, loracarbef), macrolides (erythromycin, clarithromycin), amoxicillin/clavulanate, or the standard therapy with oral penicillin V given for 10 days. Three hundred patients (6.3%) were eliminated from the data analysis; 230 (4.8%) failed to return for posttreatment assessments, and an additional 70 (1.5%) were excluded because they did not complete the full treatment course as determined by diary cards and medication returned. Because compliance of the 230 patients who failed to return is not known, the true compliance rate is between 93.7% and 98.5%.
The 2 treatment groups were comparable with regard to demographic data, environmental factors, and clinical presentations (tables 1 and 2). All patients had fever у38ЊC and у1 of the clinical symptoms listed in table 2. Evaluable patients from the study visits are summarized in figure 1 . Inadequate or absent follow-ups were the most common reasons patients were not evaluable. The reasons for nonevaluability were similar in the 5-day and 10-day treatment groups.
Clinical response. The overall clinical success rate (cure and improvement) was 94.1% at the first visit after completion of therapy (days 2-4 posttreatment) and 87.7% at the second visit (days 7-9 posttreatment) (table 3). The 2 treatment groups had equivalent rates of clinical success: 94.5% for the 5-day group and 93.4% for the 10-day group, at the first visit ( , P ! .001 equivalence test), and 87.3% versus 88.6% at the second visit ( , equivalence test). P p . 13 Resolution of clinical symptoms. The resolution of acute clinical symptoms at the 7-9-day and 12-14-day postenrollment visits was faster in the 5-day group than in the 10-day treatment group (table 4) . This difference is statistically significant (P ! ). .001
Bacteriologic response. The eradication rate of pharyngeal GABHS at the first visit after completion of treatment was 83.7% and was equivalent in the 2 treatment groups (P p ): 83.3% in the 5-day group versus 84.4% in the 10-day .022 group (table 5). The persistence of GABHS in throat cultures, with clinical symptoms, was similar in the 5-day and 10-day treatment groups. At the late follow-up visit, 6-7 weeks after end of therapy, the eradication of primary isolates was 85.6%, and the difference between the 2 treatment groups was not Downloaded from https://academic.oup.com/jid/article-abstract/182/2/509/2191408 by guest on 29 January 2019 TB3264, T13/TB3264, T28,   T11, T13, T25, T4, T9, T12, T3, T13/TB3264/T28, T12/TB3264, B3264, T8, T1,  T12/T28, T13/T28, T3264, T2, T27, T56, T5 , and T8/T25. statistically significant (85.0% in the 5-day group and 86.8% in the 10-day group; ). P p .141 Resistance to study antibiotics. No isolate of group A streptococcus was documented to be resistant to penicillin, oral cephalosporins, or amoxicillin/clavulanate used in this study. Macrolide resistance has been documented for 6 .0% of all strains tested ( ), and 6.8% have shown intermediate suscepn p 4.698 tibility. There have been geographic areas where the rate of susceptible strains decreased to 81.6% or 77.1%.
Serotyping of GABHS.
In patients with positive follow-up cultures, pretreatment and posttreatment GABHS were characterized by serotyping. Fifty-five (9.8%) of 559 patients at the 2-4-day posttreatment visit and 131 (31.0%) of 422 patients at the 6-7-week posttreatment visit had a new serotype in the follow-up culture. In 150% of recurrent infections, a new serotype could be identified (table 6) . The results were similar in the 2 treatment groups. The most frequently isolated serotypes were M1, M4, and M12 (table 7) .
Recurrence of tonsillopharyngitis.
Recurrence of clinical signs and symptoms of GABHS tonsillopharyngitis occurred in 1023 (22.8%) of 4482 patients in a 1-year follow-up period (table 8). The recurrence rate was higher in the 10-day group than in the 5-day group (24.4% and 21.9%). This difference is statistically significant ( ). P p .03 Incidence of poststreptococcal sequelae. Five of 4482 patients with a 12-month follow-up period developed signs and symptoms for the diagnosis of acute poststreptococcal sequelae: 3 patients had symptoms suggestive of rheumatic fever, according to the revised Jones criteria, and 2 patients had glomerulonephritis 2-12 months after study entry (table 9). The first preliminary results were reported in 1998 [22] .
Adverse events. Some 4,715 patients were evaluated for adverse events. The incidence of drug-related adverse events was low (99 patients, 2.1%) in both groups, and they were mainly gastrointestinal (such as vomitus, diarrhea, or abdominal pain, 65.0%) and cutaneous (skin rash, 23.1%). There were no significant differences between the 2 treatment groups ( ). P p .129
Discussion
In this large-scale study, the 5-day short-course regimens were as effective as 10 days of penicillin V in the treatment of GABHS tonsillopharyngitis in children. Equivalence was demonstrated both concerning bacteriologic eradication (P p ) and clinical success (cure plus improvement, ), .022 P ! .001 when patients were assessed at posttreatment and follow-up visits. There was no major difference when each of the 5-day regimens was compared with the 10-day regimen of penicillin V. Macrolides, however, are not the treatment of choice, because of resistant or less-susceptible strains of GABHS.
The investigators overall clinical evaluation at the 2 posttreatment visits did not correlate with the tabulation of symptoms and signs documented at these visits. In patients reported as cured (complete resolution of symptoms), symptoms were present in 31.4% (5-day group) and 44.1% (10-day group) at the 7-9-day postenrollment visit and 15.7% and 19.8% at days Table 9 . Incidence of poststreptococcal sequelae (i.e., rheumatic fever, according to the revised Jones criteria, or confirmed acute glomerulonephritis). 12-14 after enrollment. These results demonstrate that resolution of signs and symptoms is time dependent and continues after the treatment is completed. The resolution of clinical symptoms was statistically significantly faster in the 5-day short-course group compared with a 10-day regime of penicillin V. This is in agreement with results of 2 studies comparing short courses (4 days) of oral cephalosporins with a 10-day regime of penicillin V in the treatment of GABHS tonsillopharyngitis [13, 14] . Resolution of clinical signs and symptoms should be recorded in addition to the investigator's overall assessment and compared at postenrollment visits at identical end points, even if the duration of treatment is different to avoid bias caused by the investigator's interpretation of response at posttreatment evaluations. It is well understood that the efficacy of b-lactam antibiotics is related to the time that the unbound drug concentration stays above the MIC to the respective bacteria at the infection site [23] . Penicillin V may not be the best candidate, because it is not very well absorbed and is rapidly excreted. Peak serum concentrations after an oral dose of 240 mg reach only 1.0 mg/ mL and fall below the detection limit in 8 hours [24] . Hence, it is doubtful if penicillin levels are sufficiently high in the tonsillar tissue, particularly if b-lactamase-producing strains are present [25] [26] [27] [28] .
Recurrences occurred more frequently in patients treated with 10 days of penicillin (24.8%) than with the short-course therapy. This difference is statistically significant ( ) and P p .03 is in agreement with results of a 1998 study published by Pichichero et al. [9] .
Compliance was 98.5% in both treatment groups for patients who returned for posttreatment evaluations and was carefully assessed by diary cards and return of unused medication, but it is known from other studies using urinary assay as a marker of penicillin dosage that penicillinuria was present in only 66%-81% of patients treated for 10 days [11] .
The incidence of poststreptococcal sequelae documented in a 1-year follow-up was very low, and a careful analysis of each case has shown that the poststreptococcal sequelae did not occur within the time frame of the streptococcal episodes treated in this study or were not the result of these streptococcal episodes, as indicated by the patients' history (table 9) . In 1996, Snitcowsky reported that rheumatic fever and rheumatic heart disease have practically disappeared in industrialized countries but remain a serious problem in many developing countries [29] . The more severe consequences of group A streptococcal infections have become relatively uncommon in industrialized countries [30] . From this study, we have evidence that acute rheumatic fever remains very rare, indicating negligible circulation of specific rheumatogenic strains.
In conclusion, the 5-day short course of oral antibiotics used in this large-scale study was clinically and bacteriologically equivalent to a 10-day course with penicillin V, for the treatment of culture-proven tonsillopharyngitis, and did not result in more streptococcal sequelae when compared with 10-day penicillin V treatment.
